Update on Sept 13, 2024. American Express confirmed that Bluebird no longer offers new Goal balances or new family sub-accounts. The Bluebird card, offered by American Express, is an FDIC-insured ...

DEAR JOAN: A decade ago, we put up a bluebird house and followed all the directions. We are sorry to say our house is only used as a toilet! I have tried cleaning it ...

DEAR JOAN: A decade ago, we put up a bluebird house and followed all the directions. We are sorry to say our house is only used as a toilet! I have tried cleaning it ...

Bluebird bio has announced an “aggressive” plan to file three potential blockbuster drugs with regulators over the next three years, including its CAR-T therapy. Cambridge, Massachusetts-based ...

The rollout of the Somerville gene therapy company's approved medicines hasn't gone exactly to plan—and the latest round of cuts is intended to help the biotech hit its cash flow goals.

After seven years, over 3,350 patent and patent-pending claims, and more than $1 billion, AST SpaceMobile Inc. (NASDAQ: ASTS) ...

Shares of AST SpaceMobile on Wednesday climbed after the company said that it expects to launch its upcoming BlueBird satellites on or after Set. 12 from Cape Canaveral, Fla. The stock was up 11% ...

Gene therapy company Bluebird Bio on Tuesday announced a 25% reduction of its workforce as part of a restructuring meant to save money as it seeks to market its expensive but potentially life ...

As part of the restructuring, Bluebird plans to focus further on the ongoing commercial launches of LYFGENIA, ZYNTEGLO, and SKYSONA to enable continued launch acceleration while the company ...

SOMERVILLE, Mass., September 27, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the filing of its Form 10-Q for the quarter ended June 30, 2024 (the "Q2 2024 Form 10 ...

In a report released on September 24, Mani Foroohar from Leerink Partners maintained a Hold rating on Bluebird Bio (BLUE – Research ...

Bluebird Bio Inc. announced plans to cut about a quarter of its workforce as the biotech confronts a difficult environment for companies that make gene therapies, costly one-time treatments for ...